A team of Indian scientists has discovered a potential new treatment for liver cirrhosis, a serious disease that can cause severe complications. This groundbreaking research focuses on improving the body’s lymphatic system, which helps in draining excess fluid and fighting infections.
Cirrhosis is often the result of chronic liver disease and leads to scarring of the liver, affecting its ability to function. Patients with advanced cirrhosis usually experience problems like fluid build-up in the abdomen.
The research team, consisting of scientists from the Institute of Liver and Biliary Sciences (ILBS) in New Delhi and the National Institute of Pharmaceutical Education and Research (NIPER) in Guwahati, is targeting the lymphatic vessels in the liver and intestines. These vessels are crucial for making sure the body can properly drain excess fluid and maintain a healthy immune system.
To help with this, the scientists have developed a special treatment using nanocarriers filled with a powerful protein called Vascular Endothelial Growth Factor-C (VEGF-C). This protein encourages the growth of new lymphatic vessels.
Dr. Subham Banerjee from NIPER Guwahati explained that VEGF-C works by attaching to specific receptors in the body, which leads to the growth of new lymphatic channels. The team tested their approach on animal models and found that the treatment significantly improved lymphatic drainage and reduced the accumulation of fluid in the abdomen (known as ascites).
In addition to promoting better fluid drainage, the VEGF-C treatment helped lower portal pressure (the pressure in the blood vessels leading to the liver), improved immune response, and decreased bacterial infection in the body.
This innovative research opens new doors for treating advanced liver cirrhosis and restoring lymphatic function. The findings have been published in the JHEP Reports journal, highlighting their importance in medical science.
The scientists hope that, with further research and development, their treatment could soon become a viable option for patients suffering from liver cirrhosis.
-Rashmi Kumari




